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Theinfection and destruction ofTlymphocytesbyhuman immunodeficiency virus
(HIV) has been considered a central event in the pathogenesis ofthe acquired im-
munodeficiency syndrome (AIDS) (1-3). There is agrowing body ofevidence, how-
ever, that infection ofcells in the monocyte/macrophage (M/M)t series by HIV may
be clinically as important as that of T cells (4-7). Certain strains ofHIV can repli-
cate in M/M for a considerable time (>6 mo) without necessarily inducing a sub-
stantial cytopathic effect (4, 8). Such cells may thus serve as areservoir for dissemi-
nation of the virus to other cell types. Furthermore, HIV infection can perturb
accessorycell function without killing cells (9 and Mitsuyaet al., unpublished data).
In addition, M/M are believed to be important target cells in the pathogenesis of
AIDS-related dementias (10-12).
Our group has recently reported that several members ofa family ofcompounds
known asdideoxynucleosides (ddN) arepotent inhibitors ofHIVreplicationinhuman
T cells (13, 14) in vitro, and at least two such compounds, 3'-azido-2 ;3'-dideoxythy-
midine (AZT)and 2,3'-dideoxycytidine (ddC) havebeen shown to haveantiretroviral
activity in patients with AIDS and AIDS-related complex (ARC) (15-17). Several
of these drugs are currently being studied in clinical trials.
ddN are thought to require anabolic phosphorylation to an active triphosphate
moiety (ddNTP) by kinases (dN kinase) in the relevant target cells (18-21). As
triphosphates, thesecompounds act at theleveloftheviral reversetranscriptase (RT),
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competing with the normal nucleoside triphosphates (dNTP) (18, 22, 23), and pos-
sibly terminating proviral DNA chain elongation. These drugs can prevent unin-
fected cells from becoming so, but they do not eliminate virus from chronically in-
fected cells (Mitsuya et al., unpublished data).
It is known that M/M may have lower levels of nucleoside kinase activities com-
pared with replicating T cells (24), although the absolute levels of these enzymes
may be affected by the status of differentiation of M/M (25-28). It has also been
reported that certain members of the ddN family may be phosphorylated more slowly
in M/M than in T cells (24). Because of these differences and the importance of
M/M in HIV infection, we examined the ability of three ddN that are currently
being evaluated in clinical trials to inhibit HIV replication in M/M, and correlated
the activity of two of them with the concentration oftheir triphosphorylated moiety
in such cells.
In this study we have learned that each of these ddN tested can suppress the in
vitro replication of a monocytotropic strain of HIV, HTLVIIIBa-L, in M/M at con-
centrations comparable to those at which T cells are protected. We further show
that, although the phosphorylation ofat least one of these compounds, AZT, is sub-
stantially reduced in M/M as compared with T cells, there is also a parallel reduc-
tion in the levels of the competing normal dNTP. Taken together, the results suggest
that the ratio of the ddNTP to the normal dNTP may be a crucial factor in deter-
mining the activity of ddN against HIV.
Materials and Methods
Drugs. AZT (Wellcome Research Laboratories, Research Triangle Park, NC), 2',3-
dideoxycytidine (ddC), and 2',3'-dideoxyadenosine (ddA) (Pharmacia Fine Chemicals, Pis-
cataway, NY) were diluted in sterile distilled water or in RPMI 1640 and kept at 4°C until
used. ['H]ddC (sp act 27 Ci/mmol) (Research Triangle Institute, Research Triangle Park,
NC) and ['H]AZT (sp act 3 Ci/mmol) (Moravek Biochemical, Brea, CA) were stored dried
and used immediately after reconstitution.
Virus.
￿
Two different strains of HIV1, HTLVIIIR_L,a5 and HTLV IIIRi83, were used in
these experiments. HTLVIIIH;,-L, which was originally obtained from a sample of lung tissue,
and which replicates efficiently in monocytes (4), was maintained in cultures of normal pe-
ripheral blood monocytes. HTLVIII R (1), which efficiently replicates in cultured T cells, was
obtained from the concentrated supernatant of infected H9 cells (Electro-Nucleonics Labo-
ratory, Inc., Silver Spring, MD). Different strains of HIV-1 were used to infect T cells and
M/M populations because we obtained only inconsistent infection of M/M using HTLV
IIIB, and similarly inconsistent infection of immortalized T cell lines using HTLVIII ga-L .
The viral preparations were stored in liquid nitrogen. All viral preparations were tested and
found to be free of contamination with mycoplasma.
Cells.
￿
Monocyte-enriched populations of peripheral blood leukocytes were obtained from
healthy, HIV- donors, using a Fenwal C3000 cell separator. These cells were further enriched
for M/M by centrifugation over Ficoll-Hypaque (Organon Teknika Co., Durham, NC). An
additional purification of M/M was done using three different methods. (a) Fresh M/M were
obtained by elutriation using a BeckmanJ-6B centrifuge (Beckman Instruments, Palo Alto,
CA) as previously described by Gerrard et al. (29). (b) Fresh M/M were also obtained by
2-h adherence to 75-cmz plastic flasks (Costar, Cambridge, MA), in RPMI 1640 medium
(Gibco, Grand Island, NY) supplemented with 20% heat-inactivated FCS (Gibco), 2 mM
L-glutamine, 50 U/ml penicillin, and 50 wg/ml streptomycin (Gibco), referred to as complete
medium. The nonadherent cells were then removed by three washings with warm RPMI
1640 medium, and the adherent cells were detached by a 15-min incubation at 37°C with
10 ml Versene, 1 :5,000 (Gibco) at 37'C. (c) 5-d-old adherent cells were obtained by incubatingPERNO ET AL.
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106 PBMC/well in 48-well (1-cm2 well) plates (Costar) in 1 ml of complete medium. Nonad-
herent cells were removed by washing the wells several times with RPMI 1640 at 370C, and
the adherent cells were left attached. In general 0.8 x 105-1.5 x 105 viable cells remained
attached to each well, as detected by trypan blue exclusion.
Viability of the cells obtained by each of these techniques was always >95%, as determined
by trypan blue exclusion. In each population, 395% of the cells had the morphologic char-
acteristics of M/M when examined after Giemsa staining (Gibco). 5-d adherent cells were
consistently >97% positive for nonspecific esterase (Technicon Instruments Co., Tarrytown,
NY), while the elutriated and 2-h adherent cells were >8017o esterase positive when initially
prepared; these latter two preparations became >95% esterase positive after beingcultured
for 5 d in complete medium. The 5-d adherent cells were >75% positive for OKMI (Ortho
Diagnostic Systems, Inc., Raritan, NJ), while the elutriated and 2-h adherent cells were con-
sistently >95% positive for OKM1. Cells prepared by each of the techniques were <1% E-
rosette positive (30) and <I% OKTI1` (Ortho Diagnostic Systems, Inc.). Two cell lines were
used in certain experiments: ATH8, and HTLV1-infected T4' cell clone that is highly sen-
sitive to the cytopathic effect of HIV-1 (HTLVIIIB strain) (13), and H9, a T4' cell line (1);
these lines were both mycoplasma free. In some experiments, macrophage-depleted periph-
eral blood lymphocytes were used; they were consistently <2% positive by nonspecific es-
terase staining.
Assays ofAntiviral Activity.
￿
Immediately after separation, 106 fresh M/M (prepared by ei-
ther elutriation of 2-h adherence) were seeded in 24-well plates (2 cm2/well) (Costar) in 2
ml of complete medium. In some experiments, 1- or 4-cm2 well plates were used, keeping
the same cell concentration: no difference was seen in the results. Also, in a few experiments,
105 fresh elutriated M/M were cultivated in 1 ml of complete medium in 1-cm2 well plates
for 5 d before drug exposure and challenge with HTLVIIIB,-L. 5-d adherent M/M were al-
lowed to remain attached in the 1-cm2 wells in 1 ml of complete medium after the nonad-
herent cells were washed off on day 5. Neither IL-2 nor mitogens were added to any of the
M/M cultures. In preliminary experiments, we found that preincubation of M/M with poly-
brene did not improve infection of the cells (data not shown); thus polybrene was omitted
in these experiments.
Before exposure to HIV, the target cells were preexposedto various concentrations ofAZT,
ddC, or ddA for 20 min; they were then exposed to HIV without washing out the drugs.
Unless stated otherwise, 80,000 cpm/ml RT of HTLVIIIBa-L were used in the experiments;
this represented 0.16 RT cpm/cell for the elutriated and 2-h adherent cells, and 0.5-1 RT
cpm/cell for the 5-d adherent cells (depending on the number of cells remaining attached
to the wells). This dose ofvirus generally yielded the maximum infection of the M/M popula-
tions, and was 16-100 times the minimum infective dose (depending on the number of cells
present in the wells). In some experiments, 3,000 viral particles/cell of HTLVIIIB were used
to infect ATH8 or H9 T cell lines; this is 60 times the minimum infective dose for ATH8
cells. Appropriate positive and mock-infected negative controls were run for each experiment.
After infection, the cells were maintained at 37°C in a humidified atmospheresupplemented
with 5% C02. 2 d after infection, M/M were extensively washed to remove excess virus,
and cultivated in 2 ml of complete medium with the same concentration of drugs as before.
Cells were washed and fed every 4 d.
To evaluate any initial virus remaining afterwashing, in each experiment 1 ml ofcomplete
medium plus 80,000 RT cpm/ml of HTLVIIIBa-L was added to each of two wells in the ab-
sence of cells. The wells were washed and fed at day 2, and subsequently every 4 d, com-
parable to the procedure for cell-containing wells. The initially added virus was considered
absent when both wells contained undetectable HIV-p24 antigen (see below).
Viral Detection.
￿
Starting from day 3, HIV production was assessed regularly until day 28
usingtwo different methods: measurement of released RT activity, and detection of HIV-p24
antigen production in culture supernatant. To measure RT, 1 ml ofcell-free supernatant was
precipitated with 0.5 ml polyethylene glycol (mol wt 8,000) (Sigma Chemical Co.) and the
RT was assayed using a minor modification ofa technique previously described (31). Briefly,
10 ul of protein extract was incubated for 1 h at 37°C with 50 mM tris-HCI, pH 7.8, 10
MM MgC12, 10 mM DTT, 20 pM [3H]dTTP (New England Nuclear, Boston, MA) and 5111 4
￿
DDN/HIV IN MONOCYTES
ug of poly(rA)-oligo(dT),z-, 8 (Pharmacia Fine Chemicals) in a final volume of 100 ul. The
reaction was stopped with 10 wg of yeast transfer RNA plus 1 ml of chilled 10% TCA con-
taining 0.02% sodium pyrophosphate. The precipitates were collected on glass fiber filters,
washed and dried; after addition of 10 ml of nonaqueous liquid scintillation cocktail (New
England Nuclear) the radioactivity was determined with a Beckman Model scintillation spec-
trometer. HIVp24 antigen was assessed by a sandwich ELISA (Dupont Co., Wilmington,
DE). With these two methods, a small amount of residual virus (50-100 pg/ml of p24) was
sometimes present at day 3 . However, residual virus was never detected at day 7 or later.
Additional experiments were performed using unstimulated peripheral bloodlymphocytes,
H9 cells, and ATH8 cells. H9 cells were cultivated in complete medium without IL-2 . ATH8
cellswere cultured in complete medium supplemented with 15°Io human natural IL-2 (ABI,
Silver Spring, MD) and 20 U/ml human recombinant IL-2 (AMGen Biological, Thousand
Oaks, CA). In the experiment with ATH8 as a target of HIVinfection, protection from the
cytopathic effect of HIV/HTLVIIIR (a measure of antiretroviral effect) was assessed by
trypan blue exclusion as previously described (32). It is worth stressing, however, that one
must be cautious in comparing the activity of drugs in the T cell and M/M assay systems
used in this work, because different strains of HIV were, of necessity, used in the two cell
types. Drug toxicity was evaluated at various times by trypan blue exclusion in mock-infected,
drug-exposed M/M.
Metabolism ofddN.
￿
5 x 106 fresh elutriated M/M and 2-h adherent M/M (immediately
afterseparation), 5-d-old M/M (immediately afterfinal purification), and H9 cells were plated
in 2 ml of complete medium in 2-cm= well (Costar), and treated for 24 h with 0.5 PM un-
diluted, [3H]ddC, or with 10 gM undiluted, [3H]AZT The cells were then harvested (M/M
by gentle scraping followed by washing with cold RPMI), counted (viabilitywas always >92%),
and washed three times in cold RPMI to remove excess radioactivity, pelleted, and immedi-
ately frozen in dry ice. Cell pellets were then extracted with 0.5 ml 10% TCA; the acid extract
was neutralized with an equal volume of tri-n-octylamine in freon, after which the neutral-
ized extracts were analyzed via HPLC for metabolites (19, 20). Results were given as pico-
moles of ddCTP or AZTTP per 106 cells.
dNTP Pools.
￿
5 x 10' elutriated, 2-h adherent, or 5-d adherent M/M were collected im-
mediately after preparation (see above), washed at 4°C with RPMI, pelleted and stored at
- 70°C ; a similar procedure was followed for H9 cells. Endogenous dNTP pools were ana-
lyzed by anion exchange HPLC. Pellets were extracted with 10% TCA and neutralized as
shown in the previous paragraph. Ribonucleotides were degraded using a modification of
the periodate procedure of Garrett and Santi (33). The HPLC system used a Whatman Par-
tisphere 5-um SAX column (Whatman International Ltd., Maidstone, England) and a gra-
dient of 0.01-0.6 M ammonium phosphate, pH 3 .5 (19, 20).
Nucleoside Kinase Assay.
￿
10' fresh elutriated M/M, 5-d-old M/M, and H9 cells prepared
as described above were washed in cold RPMI ; the pellet was resuspended in 200 AI of 2
mM dithiothreitol (DTT) and stored at -70°C. 2'-deoxycytidine kinase (dC kinase) and 2'-
deoxythymidine kinase (dT kinase) activities were measured by a minor modification of a
published procedure (34) using 10 or 2,000 gM 2'-deoxycitidine (dC) or 430 IM dT as sub-
strate in the presence or absence of 500 wM ATP-Mg.
Results
Time Course of Infection of MIM by HTLVIII&-L.
￿
The time course of HIV
production by fresh elutriated and 5-d adherent M/M following exposure to HTLV
IIIBa_L is shown in Fig. 1. No detectable viral production was found during the first
3 d after viral exposure. However, starting at about 10 d, high-titer viral production
was obtained which was sustained for at least 4 wk. In most experiments we ob-
served greater virus production in 5-d adherent M/M than in fresh (elutriated or
2-h adherent) cells (Fig. 1) .
The efficiency of infection was dependent on the concentration ofthe added virus
(Table I). Peak infection was obtained with 80,000 RT cpm/ml of culture. WhenE
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FIGURE 1.
￿
Kinetics of HTLV11111-1- infection
in fresh elutriated M/M and 5-d-old M/M with
and without 0.1 pM ddC. (A) Fresh elutriated
M/M were exposed to 80,000 cpm RT/ml of
HTLVIIIR.A, and cultured in complete medium
as described. Thep24antigen in the supernatant
wasassayed at different times. O, Cultures with
media alone; ", cultures with 0.1 pM ddC. (B)
Same as in A, except that 5-d adherent M/Mwere
used.
higher concentrations of virus were added to the cultures, the viral production was
often lower, possibly because of early interference by incomplete viral particles. It
is also conceivable that a cytopathic effect of the viral preparation may have con-
tributed to this; however, little or no cell death was observed when HTLVIIIBa-L-
exposed M/M were assessed by trypan blue exclusion.
Little or no viral production was found in cultures of monocyte-depleted PBL
exposed to HTLVIIIBa-L in the absence of PHA and IL-2 (results not shown).
Anti-HIV Activity of ddN in M/M.
￿
Based on these initial experiments, we exam-
ined the anti-HIV effect of several ddN in cultures of M/M exposed to 80,000 RT
cpm/ml of HTLVIIIBa-L. In cultures of fresh M/M (obtained either by elutriation
or by 2-h adherence), we found >_95 % suppression of HIV replication with concen-
trations of 0.05 gM AZT, 0.01 uM ddC, or 0.05 wM ddA (Figs. 1 and 2). These
concentrations of drugs are lower than those required to suppress the virus in H9,
a replicating T cell line, against infection with the T cell-tropic virus HIV/HTLV
TABLE I
Viral Production in Fresh Elutriated MIM Exposed to Different Doses
of HIV1HTLV-IIIBa-[,
HIV added to the
cultures at day 0
cpm RT/ml
HIV
Day 14
p24 antigen in M/M
supernatants
Day 21
Pg/ml
culture
Day 28
20,000 <15 722 7,165
80,000 345 65,368 52,453
320,000 49 23,097 46,4601116
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FIGURE 2.
￿
Viral suppression as a function of drug concentration in M/M andH9 cellsexposed
to HIV-1 in presence of various concentrations of ddN. (A) Protection by AZT as assessed by
HIV p24 antigen at day 14 (top) and day 21 (bottom). The cells tested are as follows: i, fresh
elutriated M/M; O, 5-d-old adherent M/M; 0, H9 cells. HTLVIIIBa_L was used to infect the
monocytes and HTLVIIIB was used to infect the H9 cells. Control p24 antigen production
(without drugs) is as follows: Fresh elutriated M/M, 1,300 pg/ml at day 14 and 48,500 pg/ml
at day 21; 5-d M/M, 36,000 pg/ml at day 14 and 320,700 pg/ml at day 21; H9 cells, 105,000
pg/mlat day 14 and98,000 pg/mlat day 21. (B)Protection by ddC, expressed in asimilarmanner.
(C) Protection by ddA, expressed in a similar manner.
IIIB (Fig. 2). Protection was sustained throughout the 28-d culture period (Fig. 1
a). In additional experiments, no viral production was detected when either fresh
or 5-d adherent M/M were exposed up to 320,000 cpm/ml RT of HTLUIIIaa_L in
the continuous presence of 0 .5 gM ddC (data not shown).
Each of the ddN tested could also suppress HTLUIIIBa -L replication in 5-d ad-
herent M/M, although in this cell population somewhat higher concentrations of
drugs were required. In most experiments, we observed >95% inhibition of viral
replication in 5-d-old M/M with 0.1 4M AZT, 0.1 4M ddC, or 1 pM ddA (Fig.
2). Similar results were obtained when less virus (20,000 cpm RT/ml) was used to
infect the cells. Again, viral inhibition was sustained for each drug during the whole
28-d period assayed. In additional experiments, we examined the effect of ddN on
HIV infection of fresh elutriated M/M that were allowed to mature for 5 d in culture
before being exposed to virus (Table II). AZT was slightly less potent in this cell
population than in either fresh or 5-d adherent cells; the ID-so was -0.1 tIM. The
activities of ddC and ddA were roughly similar in these cells to their activity in 5-d
adherent cells (ID5o ^0.001 pM for ddC and 0.1-1 gM for ddA).
In some experiments, elutriated or 5-d-old M/M were subjected to three cycles
of freezing and thawing at day 21, with the aim ofreleasing viral antigens that might
be in the macrophages; this technique has been shown to be effective at releasing
viral antigens in other cell culture systems (35) and has been recently reported by
Gendelman et al. (36) to induce the release of RT from HIVinfected macrophages
cultured with colony-stimulating factor. No additional p24 antigen was detected in
the supernatants after this procedure (data not shown). Also, in three different ex-
periments, HIV production was assayed by a determination of RT activity in cul-
ture supernatants; these results were essentially parallel to those assessed by p24 an-
tigen production (data not shown). Finally, M/M exposed to high multiplicity of
infection of HIV-1 in the form of HTLUIIIB (a viral isolate that can readily repli-
cate within T cells) showed inconstant low-level infection; however the viral produc-
tion that did occur was consistently inhibited by ddN (data not shown)._X
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TABLE 11
Suppression of HTLV-III11a-L Replication by AZT, ddC, and ddA
in Elutriated MIM Cultivatedfor 5 d before Viral Exposure
105 elutriated M/M were cultivated for 5 d in 1 ml of complete medium.
They were then exposed to AZT, ddC, or ddA for 20 min and challenged
with HTLV-IIIBa-L 80,000 RT cpm/ml (0.8 RT cpm/cell) while main-
taining the drugs in the media. Viral replication was assessed at day 21
by HIV-p24 antigen production.
Consistent with the monocytotropic nature ofHTLVIIIBa-L, ATH8 cells (an im-
mortalized T cell clone) exposed to HTLVIIIBa-1. at 80,000 RT cpm/ml failed to
produce detectable virus up to day 14 after viral exposure, while only transient and
low-level viral production was observed in H9 T cells exposed to this strain. Using
HTLVIIIB, >95% protection at day 14 was obtained in both T cell lines with 2 PM
AZT, 0.5 gM ddC, or 5 gM ddA. These concentrations of ddN (Fig. 2 and data
not shown) are somewhat higher than those requiredto protect M/M; however, one
must use caution in making stringent comparison between M/M and H9, because
differentstrainsofviruswere used indifferent cells. Atday 21 therewasaviralbreak-
through in H9 cells with AZT, even at the highest dose tested (10 gM) (Fig. 2 A),
in agreement with previously reported results (37, 38).
Notoxicity (asassessed by trypan blueexclusion) wasobserved inM/M(prepared
by any of the three methods) exposed for 14 d to up to 20 gM AZT, 2 gM ddC,
and 100 gM ddA (Fig. 3); thus the doses of ddN that induced viral inhibition in
M/M are much lower(at least 20-200 times) than those necessary to kill the target
02 2 20 .02 02 2
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FIGURE 3.
￿
Toxicity ofAZT, ddC, and
ddA in elutriated M/M. M/M were
cultivated in 2 ml ofcomplete medium
in 2-cm2 wells, in presence of various
concentrations ofAZT, ddC, and ddA.
After 14 d, M/M were detached by ver-
sene plus scraping, and were counted
in ahemocytometerchamber; viability
was evaluated by trypan blue exclusion.
As additional control, the same experi-
ment was run in polypropylene tubes
using the same experimental condi-
tions: no difference was seen in the
results.
Drug Concentration HIV-p24 antigen level Viral suppression
AM pg1Ml 1 70
No drug - 57,200 0
AZT 0.01 42,304 26
0 .1 33,017 43
1 4,162 93
10 <31 100
ddC 0 .001 34,175 40
0.01 <31 100
0.1 <31 100
ddA 0 .01 66,428 0
0.1 49,824 13
1 <31 100111 8
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cells. Therefore, it is unlikely that the antiviral effect of ddN is an artifact of drug
toxicity. Thus, although there were some differences between fresh and 5-d adherent
M/M, both populations could be protected against HIV infection with each of the
ddN congeners tested .
To better define the basis ofthis antiviral activity, we evaluated the anabolic phos-
phorylation of AZT and ddC in M/M and compared it with the phosphorylation
in H9 T cells. In addition, we examined the pool size of the endogenous normal
dNTP, 2'-deoxythymidine-5'-triphosphate (dTTP), and 2'-deoxycytidine-5'-triphos-
phate (dCTP) in each of these cell populations. As seen in Table III, similar levels
of ddCTP were produced in fresh-elutriated M/M and H9 cells exposed to 0.5 AM
of [3H]ddC for 24 h, while 5-d adherent M/M cells accumulated slightly lower levels
ofddCTP A typical chromatographic elution pattern of ddC and its phosphorylated
metabolites in elutriated M/M and H9 cells is illustrated in Fig. 4 A . In addition,
fresh elutriated M/M and H9 cells had comparable activity of dC kinase, the en-
zyme that catalyzes the first phosphorylation ofddC (Table IV); 5-d adherent M/M
expressed somewhat lower dC kinase activity. Since ddCTP is thought to compete
with the normal dCTP at the level of viral reverse transcriptase, we further exam-
ined the level of dCTP in these cell populations. As can be seen in Table III, the
levels of dCTP in either M/M population were <20% of that in H9 cells. Thus,
the protective effect of ddC in M/M, in spite of somewhat reduced ddCTP forma-
tion, may have been produced by a substantially lower competing dCTP pool size
in these cells.
When AZT metabolism was examined in thesecells, a somewhat different pattern
was seen . Both fresh elutriated and 5-d adherent M/M exposed to 10 AM [3H]AZT
for 24 h had substantially reduced levels of AZTTP as compared with H9 T cells
(Table III). A typical chromatogram is shown in Fig. 4 B. Also the levels of dT ki-
nase activity were markedly reduced in the M/M cells as compared with T cells
(Table IV) . However, when dTTP was assayed, both M/M populations had <5%
of the concentration ofdTTP found in H9 T cells (Table III) . Thus, although AZT
is phosphorylated less efficiently in M/M than in H9 T cells, there are substantially
reduced levels of the competing dTTP in M/M; as a result the ratio of AZTTP to
dTTP is roughly similar in M/M to that in H9 T cells.
TABLE III
Phosphorylation of ddC and AZT to the 5'-Triphosphate, and Levels
of Corresponding Normal Nucleoside Triphosphates in
Monocyte/macrophages and H9 T Cells
Results shown for dCCTP and AZTTP are the mean ± SD of three
to six experiments. For dCTP and dTTP, the results are the average
of two experiments.
* dCCTP in cells exposed to 0.5 pM 13H1ddC for 24 h.
dCTP or dTTP in cells not exposed to drugs.
S AZTTP in cells exposed to 10 WM 13HJAZT for 24 h.
dCCTP* dCTP$
pmolel]06 cells
AZTTPS dTTPI
Elutriated M/M 0.82 +_ 0 .19 1 .95 0.034 + 0.018 0.58
5-day-old M/M 0.64 f 0.36 2 .45 0.082 ± 0.033 0.76
H9 cells 0.93 ± 0.37 15.4 0.31 ± 0.12 21 .45PERNO ET AL.
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FIGURE 4.
￿
Typical ion-exchange (Partisil-10 SAX) HPLC elution profile of 100 /0 TCAextracts
of H9 T cells and fresh elutriated M/M incubated for24 h with 0.5 PM [3H]ddC (A) or 10 pM
[3H]AZT (B). Analyses were carried out using radial compression columns of Partisil-10 SAX
equilibrated anddevelopedwith 0.01 M ammonium phosphate, pH 3.6, for 15 min followed by
a linear gradient to 0.6 M ammonium phosphate, pH 3.8, over the next 25 min, and finally by
a 5 min isocratic elution with 0.6 Mammonium phosphate, pH 3.8. TCAextracts were neutral-
ized with tri-n-octylamine in freon before analyses. Sample volume: 200ul. 1-min fractionswere
collected and data are expressed as femtomoles per fraction per 106 cells. The AZTMP peak
in Bfor the H9 cells extract is off-scale forthe 20-, 21-, and22-min fractions: the AZTMPvalues
for these fractions were 3,888, 7,557, and 2,524 fmoles/fraction/106 cells, respectively. Q, Elutri-
ated M/M; O, H9 T cells.
The ddA metabolism was not evaluated because of the technical difficulty in ac-
curately measuring the final product of ddA anabolism, 2',3'-dideoxyadenosine-5'-
triphosphate (ddATP). However the concentrations ofendogenous 2'-deoxyadenosine-
5'-triphosphate (dATP) in both fresh and 5-d adherent M/M was <0.5 pmole/106
cells, compared with 17.35 pmole/106 cells in H9 cells. Thus, in the case of ddA as
well, a small pool size of the competing dNTP in M/M may permit anti-HIV ac-
tivity of ddA even if its level of phosphorylation is low.
Discussion
It has become increasingly apparent that infection of cells of the M/M lineage
by HIV plays an important role in the pathogenesis of AIDS (4, 39). As these cells
may be resistant to the cytopathic effect of HIV, once infected, they could persis-
tently produce HIV (4, 7, 8). Because of this, they could serve as a reservoir of HIV
and in this context frustrate certain antiretroviral chemotherapies. In addition, since
HIV envelope-induced syncytia formation can lead to T cell death without the need
TABLE IV
2'-Deoxycytidine Kinase and 2'-Deoxythymidine Kinase in Fresh Elutriated M/M, 5-d-old
M/M, and H9 T Cells
Results shown are the mean t SD of three experiments . dCMP, 2'-deoxycytidine-5'-mono-
phosphate; dTMP, 2'-deoxythymidine-5'-monophosphate.
2'-Deoxycytidine kinase
pmole dCMPlmg protein/min
2'-Deoxythymidine kinase
pmole dTMPlmg proteinlmin
Elutriated M/M 9.44 ± 2.33 34.2 ± 14.05
5-d-old M/M 2.62 t 1.59 5.7 ± 1 .11
H9 cells 9.07 f 2.52 407.7 + 161.51120
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for such T cells to become infected per se, HIVproducing macrophages could theo-
retically cause T cell depletion even if the T cells are rendered virally resistant by
drugs (40, 41). Finally, M/M are an important target cell for HIV in the brain (10,
11) and thus may play a role in the pathogenesis of HIV-induced dementia (12, 39).
For these reasons, it is crucial that an antiviral strategy for HIV infection somehow
address the infection of M/M by the virus.
Mature M/M have a limited proliferative potential, and certain studies of these
cell populations (42-44) have suggested that they may phosphorylate nucleosides
poorly as compared with dividing lymphocytes. In agreement with previous studies
of others (24), we found in these experiments that the phosphorylation (metabolic
activation) of at least one ddN analogue, AZT, was substantially reduced in mono-
cytes; however, the metabolic activation of another dideoxynucleoside, ddC, was
roughly comparable to that in T cells. It was therefore somewhat surprising that
HIV replication could be suppressed in M/M by each ddN tested (including AZT)
at concentrations comparable to those at which the drugs inhibit HIV in T cells.
To further explore this apparent incongruity, we examined the level of dTTP and
dCTP in the M/M populations, and found that the level of dCTP was six to eight
timeslower than that in T cells, and the level of dTTP was substantially lower (30-35
times). Thus, in the M/M populations, the ratio of the ddNTP to the corresponding
normal dNTP was equal or greater than that found in T cells. There are two known
mechanisms by which ddNTP inhibit the replication of HIV (and other retroviruses)
(18, 21, 45, 46) . One is that they act as competitive inhibitors of the corresponding
dNTP at the level of HIV's DNA polymerase (reverse transcriptase) with K; of
0.04-0.2 gM (18, 21-23). The major cellular DNA polymerase (DNA polymerase
a) is rather resistant to these drugs (47). In addition, because of the replacement
of their 3'-hydroxy group with hydrogen or another group, once these compounds
are incorporated at the end of a growing chain of viral DNA, no further nucleotide
residues can be added. Thus they can act as chain terminators after having elon-
gated a growing chain of DNA by one residue (18, 21, 45). It therefore follows that
the activity of ddN in a given cell will be heavily affected by the ratio of the ddNTP
level to the normal endogenous dNTP level, and this may account for the activity
of AZT in M/M in spite of the limited phosphorylation of this drug.
M/M are a heterogeneous population, and one must be cautious in extrapolating
the results here to other populations of these cells. Certain subsets of M/M and/or
M/M belonging to the same subpopulation but at different stage ofmaturation could
exhibit variability in HIV replication, drug activation, or both. We have tried in
part to address this by examining M/M prepared by several methods (including cells
allowed to adhere and differentiate for 5 d). Nevertheless, it is still possible that HIV
replication in certain differentiated macrophages may be inhibited only by higher
concentrations of ddN, and that not all cells within our heterogeneous populations
are rendered virally resistant by these agents.
In this regard, it is worth pointing out that Richman et al. (24) have recently reported
that AZT, ddC, and ddA failed to inhibit HIV infection of monocytes prepared by
3-7-d adherence (24). There are a number of differences in the experimental tech-
niques used by that group and those used by us in this study; for example, Richman
et al. used HIVLAV-z (a T cell-tropic strain), did not preincubate the cells with
drugs, and examined protection after 3 d in culture (24), whereas we used aPERNO ET AL.
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monocytotropic strain of the virus, preincubated the cells with drugs for 20 min
before viral infection, and examined the antiviral effect over a 28-d period . It is pos-
sible as well that subtle differences may have affected the M/M populations in these
two studies and influenced the results. It has been shown that M/M digesting cel-
lular debris, for example, normally excrete nucleosides (such as thymidine) (44).
Thymidine can outcompete (nullify) the antiviral activity ofAZT (13, 32). At the
same time, after anabolic phosphorylation, thymidine can potentiate the activity
ofddC, inpart by complex allostericeffects acting atthe level ofribonucleotide reduc-
tase, to reduce cellular dCTP pools (48). It is thus conceivable that in crowded cul-
tures ofmacrophages actively phagocytosingcellular debris, theremay be avariable
patternofantiviral effect inducedbyddN, leadingtodifferentobservations andcon-
clusions. Finally, our current data do not address subtle perturbations of accessory
cell function that theoretically could occur even though an ongoing state of viral
replication did not exist.
Our results do suggest, however, that HIV replication in fresh peripheral blood
M/M can be efficiently suppressed byAZT, ddC, or ddA, and that certaindifferen-
tiated (5-d-cultured) populations can also be rendered resistant to viral replication.
It is unlikely that these results were due to contaminating T cells in the populations
because (a) ourpopulations contained <1To Tcells, (b) we did not stimulatethe cells
with IL-2 or PHA, and (c) we used a monocytotropic strain of HIV that infects
T cellsless efficientlythan M/M. The results suggest, at minimum, that the periph-
eral blood monocytes, which may disseminate HIV through the immune system,
can be protected against HIV infection byddN under someconditions. These results
may also have implications in understanding the effects ofthese drugs on virus in
thecentral nervoussystem. Wehave foundthat HIVinduceddementia may be reversed
in certain patientsby the administration ofAZT(49, 50). It is possible that the pro-
tection of M/M in the central nervous system (e.g. microglial cells) by AZT may
have contributed to the clinical improvement in these patients.
As a final point, however, itshould be reemphasized thatddNdonot substantially
reduce HIV expression in Tcells that are already infected (Mitsuya et al., unpub-
lished data). We do not know how long infected M/M produce virus in vivo, but
such long-lived infected cells may pose a problem for antiretroviral therapy even
ifde novo infection and recruitment ofnew cells can be blocked. Further study of
the patterns ofinfection ofM/M in vivo will thus be important in designing ther-
apeutic strategies for the antiviral therapy of HIV infection.
Summary
Becauseoftheprobable role ofHIV-infected monocyte/macrophages in thepatho-
genesis and progression ofAIDS, it is essential that antiretroviral therapy address
viral replication in cellsofthis lineage. Severaldideoxynucleosides have been shown
tohave potent invitro and, inthecase of3'-azido-2,3'-dideoxythymidine (AZT) and
2',3'-dideoxycytidine (ddC), in vivo activity against HIV. However, because these
compounds must be phosphorylated (activated) in target cells, and because mono-
cyte/macrophages may have levels ofkinases that differ from those in lymphocytes,
we investigated the capacity of these drugs to suppress HIV replication in rnono-
cyte/macrophages using HIV1/HTLVIIIBa-L (a monocytotropic isolate). In the
present study, we observed that HTLVIIIBa-L replication in fresh human periph-112 2
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eral blood monocyte/macrophages was suppressed by each of three dideoxynucleo-
sides: 3'-azido-2,3'-dideoxythymidine (AZT), 2',3'-dideoxycytidine (ddC), and 2',3'-
dideoxyadenosine (ddA). Similar results were observed in 5-d-cultured monocyte/mac-
rophages, although higher concentrations of the drugs were required. We then studied
the metabolism of AZT and ddC in such cells. The phosphorylation of ddC to a
triphosphate moiety was somewhat decreased in monocyte/macrophages as com-
pared with H9 T cells. On the other hand, the phosphorylation of AZT in mono-
cyte/macrophages was markedly decreased to 25 % or less ofthe level in T cells. How-
ever, when we examined the level of the normal endogenous 2'-deoxynucleoside
triphosphate pools, which compete with 2,3'-dideoxynucleoside triphosphate for viral
reverse transcriptase, we found that the level of2'-deoxycytidine-triphosphate (dCTP)
was six- to eightfold reduced, and that of 2'-deoxythymidine-triphosphate (dTTP)
was only a small fraction of that found in T cell lines. These results suggest that
the ratio ofdideoxynucleoside triphosphate to normal deoxynucleoside triphosphate
is a crucial factor in determining the antiviral activity of dideoxynucleosides in HIV
target cells, and that the lower levels of dTTP may account for the antiretroviral
activity of AZT in the face of inefficient phosphorylation of this compound.
The authors wish to thank Dr. H. Mitsuya for helpful discussions, P. Fratantoni for blood
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